Oral GLP-1 vs. injection.
The gap just narrowed. Foundayo (orforglipron) was approved on April 1, 2026 — the first small-molecule oral GLP-1, with no food or water restrictions and ~12.4% body-weight loss at the highest dose. Here's how it stacks up against Rybelsus, Wegovy, and Zepbound — and what's still genuinely different about an injection.
~21%Zepbound mean loss · 72 wk
~12.4%Foundayo 17.2 mg · 72 wk · oral
~3.7%Rybelsus 14 mg · 26 wk · oral (legacy)
For the first time, an oral GLP-1 reaches double-digit percentage weight loss without an empty-stomach ritual. The gap to top-tier injectables is no longer 4× — it’s closer to 1.7×, and the lifestyle math changes accordingly.
The first true convenience oral
Small-molecule, non-peptide, once daily, any time. ATTAIN-1 showed ~12.4% body weight loss at 72 weeks. From $149/month via LillyDirect.
Oral sema 50 mg
Novo’s higher-dose oral semaglutide. OASIS-1: ~15.1% at 68 weeks. Empty-stomach ritual still required.
Eight metrics that actually matter
FDA-approved oral GLP-1 today
OralFoundayo (orforglipron, daily, any time) · Rybelsus (semaglutide 14 mg, empty stomach)
InjectionWegovy, Zepbound, Mounjaro, Trulicity, Ozempic
Mean weight loss · current approvals
Oral~12.4% at 72 wk (Foundayo 17.2 mg) · ~3–4% at 6 mo (Rybelsus 14 mg)
Injection~15% (Wegovy) to ~21% (Zepbound) at 68–72 weeks
Dose schedule
OralFoundayo: daily, any time, with or without food · Rybelsus: empty stomach + ≤4 oz water + 30-min fast
InjectionOnce weekly, no food/timing rules
Bioavailability
OralFoundayo: high (small molecule) · Rybelsus: ~1% (peptide + SNAC)
Injection~89% (Wegovy)
Onset of effect
OralSteady-state within ~4–5 weeks across the oral options
InjectionSteady-state within ~4–5 weeks
Cash list price · monthly
OralFoundayo: $149 (0.8 mg) → $349 (17.2 mg) via LillyDirect · Rybelsus: $950–$1,150
Injection$1,060–$1,350 (Wegovy/Zepbound)
Travel & lifestyle
OralNo injection supplies, no refrigeration, fits in any pill organizer
InjectionRefrigeration required after first use; sharps disposal
What's coming next
OralOral semaglutide 25/50 mg under FDA review · second-generation small molecules in Phase 2
InjectionRetatrutide (triple agonist, ~2027); CagriSema; survodutide
Why oral loses 99% of its dose
Semaglutide is a 31-amino-acid peptide. Peptides are normally digested in the stomach and intestines before reaching the bloodstream — the same system that breaks down protein from a steak.
Rybelsus solves this by co-formulating semaglutide with a molecule called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate). SNAC briefly changes the local pH in the stomach lining, neutralizes acid in a small zone around the tablet, and helps a fraction of the semaglutide cross the gastric mucosa directly into the portal vein.
The window is narrow. Food, water beyond the allowed 4 oz, or other medications in the stomach disrupt the local pH shift and reduce absorption. The required 30-minute empty-stomach ritual exists for this reason — it is not pharmacist habit, it is pharmacology.
Even with SNAC, bioavailability is roughly 1%. A 14 mg tablet delivers a circulating semaglutide level equivalent to about 0.14 mg subcutaneously — far below the 2.4 mg ceiling that produces the Wegovy weight-loss results.
What changed with Foundayo:orforglipron is not a peptide. It is a small molecule that activates the GLP-1 receptor with a different chemical structure entirely. Stomach acid does not break it down; food does not interfere with absorption; bioavailability is high enough to reach therapeutic blood levels with a normal breakfast or empty stomach. ATTAIN-1 confirmed ~12.4% mean body weight loss at 72 weeks — not the 21% ceiling of Zepbound, but well past anything an oral option had reached before, with none of the ritual.
Who each form is actually right for
Choose injection if…
Most people- You're targeting weight loss above 10% — current orals don't reliably get there.
- You don't want to plan around a 30-minute empty-stomach window every morning.
- You have a coffee-and-news routine you don't want to renegotiate.
- You can manage a once-weekly injection (most people, after the first one, describe it as a non-event).
- Your insurance covers Wegovy, Zepbound, or Mounjaro — coverage is meaningfully more common than for Rybelsus' obesity-equivalent dose, since that doesn't yet exist.
Choose oral if…
Now viable- Needle aversion is genuinely deal-breaking for you.
- You're targeting 10–15% loss and Foundayo's 12% mean is in your acceptable range.
- You travel frequently and can't deal with refrigerated injectables in the field.
- Cash pricing matters: Foundayo opens at $149/month vs. $1,000+ for branded injectables.
- You're managing T2D and want a tablet alongside metformin.
Foundayo is the practical choice today; Rybelsus remains relevant only for patients already responding to it.
Common questions about oral vs. injectable GLP-1s
We answer what we hear most often from readers. Have one we haven’t covered? Send it our way.
At currently approved doses, no. Rybelsus 14 mg gives roughly 3–4% body weight loss at 6 months — meaningfully less than Wegovy's ~15% at 68 weeks. The OASIS trials of higher-dose oral semaglutide (25 mg and 50 mg) showed up to 15% weight loss at 68 weeks, but those doses are not yet approved for obesity as of early 2026.
Semaglutide is a peptide. Peptides are normally digested by stomach acid and enzymes before they reach the bloodstream. Rybelsus combines semaglutide with an absorption enhancer called SNAC that briefly raises local pH and helps the molecule cross the gastric mucosa. Food, drink, or other meds in the stomach interferes with this window — hence the 30-minute empty-stomach rule.
If approved, yes. Orforglipron is a small molecule, not a peptide — bioavailability is high enough to dose like a normal pill. Phase 2 weight loss was ~14.7% at 36 weeks at the highest dose, comparable to Wegovy. Lilly has filed in 2025; FDA decision is expected in 2026.
Most patients describe modern GLP-1 pens as no more uncomfortable than a vaccine, often less. Pens like Trulicity hide the needle entirely and dose with one button. Compounded vial-and-syringe kits require more steps but use very fine 27-31 gauge needles. Needle anxiety is real, but in practice the injection itself is rarely the deal-breaker that patients fear.